Skip to main content

Advertisement

Table 2 Toxicity possibly, probably, or definitely attributable to chemotherapy (n = 51)

From: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Adverse events Grade 1 Grade 2 Grade 3 Grade 4 Total
No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%)
Hematological
 Leucopenia 15 29.4 17 33.3 1 1.96 1 1.96 34 66.7
 Neutropenia 13 25.5 13 25.5 5 9.8 2 3.9 33 64.7
 Anemia 12 23.5 10 19.6 3 5.9 0 0 25 49.0
 Thrombocytopenia 7 13.7 11 21.6 7 13.7 4 7.8 29 56.9
Non-hematological
 Hepatic dysfunction 19 37.3 3 5.9 1 1.9 0 0 23 45.1
 Nausea/vomiting 15 29.3 11 21.6 2 3.9 0 0 28 54.9
 Neurotoxicity 12 23.5 3 5.9 2 3.9 0 0 17 13.7
 Hand-food syndrome 12 23.5 5 9.8 2 3.9 0 0 19 37.3
 Anorexia 8 15.7 0 0 1 1.9 0 0 9 17.6
 Diarrhea 5 9.8 4 7.8 2 3.9 0 0 11 21.6
 Infusion reaction 3 5.9 2 3.9 0 0 0 0 5 9.8
 Fatigue 1 1.9 3 5.9 1 1.9 0 0 5 9.8
 Arrhythmia 2 3.9 3 5.9 0 0 0 0 5 9.8